Coreexome 24 array

Manufactured by Illumina

The CoreExome-24 array is a high-throughput genotyping platform that enables analysis of genetic variations across the genome. It is designed to deliver comprehensive coverage of common and rare variants for a range of research applications.

Automatically generated - may contain errors

Lab products found in correlation

Humanexome 12, by Illumina (1 mentions)

Close spelling variants of this product

CoreExome (7 citations) CoreExome-24 (4 citations) Infinium CoreExome-24 bead arrays (3 citations) Infinium CoreExome 24 array (2 citations)

2 protocols using coreexome 24 array

Comprehensive Genomic Analysis Pipeline

Cited 3 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

ES analysis was performed at BG as previously described^{32 (link)}. Samples were also concurrently analyzed by SNP arrays (Illumina HumanExome-12 or CoreExome-24 array) for quality control of the ES data, as well as for detecting large copy-number variants (CNVs) and regions of absence of heterozygosity (AOH)^{33 (link),34 (link)}. Homozygous/hemizygous deletions were also analyzed using an in-house developed pipeline based on exome read-depth analysis as previously described^{35 (link)}. The ES-targeted regions cover >23,000 genes for capture design (VCRome by NimbleGen^®), including both coding and untranslated region exons. The mean coverage of target bases was >100×, and >95% of target bases were covered at >20×^{32 (link)}. PCR amplification and Sanger sequencing was performed to verify all candidate variants in the probands according to standard procedures. Of note, reanalysis of ES data for individuals who had their first ES analysis prior to January 2020 was performed as described recently^{36 (link)} to evaluate for the presence of other potentially causative variants. No other potential molecular diagnoses contributed by other loci were identified by the reanalyses.

Okur V., Chen Z., Vossaert L., Peacock S., Rosenfeld J., Zhao L., Du H., Calamaro E., Gerard A., Zhao S., Kelsay J., Lahr A., Mighton C., Porter H.M., Siemon A., Silver J., Svihovec S., Fong C.T., Grant C.L., Lerner-Ellis J., Manickam K., Madan-Khetarpal S., McCandless S.E., Morel C.F., Schaefer G.B., Berry-Kravis E.M., Gates R., Gomez-Ospina N., Qiu G., Zhang T.J., Wu Z., Meng L., Liu P., Scott D.A., Lupski J.R., Eng C.M., Wu N, & Yuan B. (2021). De novo variants in H3-3A and H3-3B are associated with neurodevelopmental delay, dysmorphic features, and structural brain abnormalities. NPJ Genomic Medicine, 6, 104.

+ Open protocol

+ Expand

Michigan Genomics Initiative for Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols

The Michigan Genomics Initiative (MGI) is a collaborative research effort among physicians, researchers, and patients at the University of Michigan funded through Precision Health. Recruitment started in 2012 and >85K individuals of at least 18 years of age have been recruited to the study as of the end of 2021 (Zawistowski et al., 2021 (link)). In brief, genotypes of 570k genetic variants were obtained using a customized Illumina Infinium CoreExome-24 array; imputation using the Haplotype Reference Consortium (HRC) panel resulted in >32 million genotypes. T1D and T2D cases of European genetic ancestry between 40–69 years of age (to agree with the sample selection in our primary UKB analysis) were derived from a subset of the MGI study (the Michigan Genomics Initiative-Metabolism, Endocrinology & Diabetes (MGI-MEND) cohort) of 4,108 individuals in which T1D and T2D cases have been carefully defined by direct clinician visits (Zawistowski et al., 2021 (link)). Similarly, we identified controls of European genetic ancestry between 40–69 years of age as individuals without diabetes inclusion ICD code or having an exclusion code (ICD-10 or ICD-9) listed in Supplementary Table 3.

Shoaib M., Ye Q., IglayReger H., Tan M.H., Boehnke M., Burant C.F., Soleimanpour S.A, & Gagliano Taliun S.A. (2023). Evaluation of polygenic risk scores to differentiate between type 1 and type 2 diabetes. Genetic epidemiology, 47(4), 303-313.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!